<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857099</url>
  </required_header>
  <id_info>
    <org_study_id>CHUB-Kemani</org_study_id>
    <nct_id>NCT04857099</nct_id>
  </id_info>
  <brief_title>Impact of the Navilas ® Micropulse Laser Treatment for Macular Edema Within the CHU Brugmann Hospital Macular Edema</brief_title>
  <official_title>Retrospective Study Within the Brugmann University Hospital of the Navilas ® Micropulse Laser Treatment for Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brugmann University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brugmann University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Navilas® micropulse laser can be used to treat patients with macular edema and good&#xD;
      visual acuity, which therefore do not fall within the indications for conventional treatments&#xD;
      by intravitreal injections.&#xD;
&#xD;
      The CHU Brugmann Hospital is the only center to own this laser in Belgium.This study aims to&#xD;
      evaluate the efficacy of this laser.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Baseline versus three months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal thickness change</measure>
    <time_frame>Baseline versus three months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Periodicity of anti-VEGF injections</measure>
    <time_frame>Baseline versus three months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Scar - assessed by optical coherence tomography</measure>
    <time_frame>Three months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Scar - assessed by fluorescein angiography</measure>
    <time_frame>Three months after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Scar - assessed by auto-fluorescence fundus images</measure>
    <time_frame>Three months after treatment</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Macular edema</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data extraction from medical files</intervention_name>
    <description>Data extraction from medical files</description>
    <arm_group_label>Macular edema</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Retrospective study including 23 files of patients treated with the Navilas ® micropulse&#xD;
        laser, in the period from 04/25/2018 to 11/10/2020&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diffuse macular edema without focal edema source accessible by focal laser (e.g.&#xD;
             capillary telangiectasia)&#xD;
&#xD;
          -  Central retinal thickness ≤ 400microns.&#xD;
&#xD;
          -  Patient does not meet the reimbursement criteria for intra-vitreous injections(IVI) of&#xD;
             anti-VEGF (eg AV&gt; 5/10).&#xD;
&#xD;
          -  IVI are contraindicated.&#xD;
&#xD;
          -  Physician considers that it is preferable to space out the injections because of the&#xD;
             side effects (eg. ocular disturbance during IVI, eye pain, sensation of a foreign&#xD;
             body, spots in the visual field generating a visual gene etc.)&#xD;
&#xD;
          -  Patient wishing to space the anti-VEGF IVI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macular edema of a different etiology than diabetic macular edema or venous thrombosis&#xD;
             (e.g. cataract extraction, vitreomacular traction, epiretinal membrane etc.)&#xD;
&#xD;
          -  Central retinal thickness &gt; 400 microns.&#xD;
&#xD;
          -  The eye presents a focal edematous maculopathy accessible to conventional laser.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Kemani</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roman Kemani</last_name>
    <phone>3224772407</phone>
    <email>roman.kemani@ulb.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Postelmans, MD</last_name>
      <phone>3224772407</phone>
      <email>laurence.postelmans@chu-brugmann.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brugmann University Hospital</investigator_affiliation>
    <investigator_full_name>Laurence Postelmans</investigator_full_name>
    <investigator_title>Head of the Ophtalmology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

